This article is more than 5 years old. Information may no longer be current.
Akorn names new CEO
Click Here to Manage Email Alerts
Akorn Inc. has named Douglas S. Boothe as its new president and CEO, effective Jan. 1, 2019, the company announced in a press release.
“I am excited and humbled with the opportunity to lead Akorn and our dedicated employees as we focus our energies toward expanding our offerings to customers, improving our financial performance and enhancing long-term shareholder value,” Boothe said in the release.
Boothe previously served as president of the generics division of Impax Laboratories, a developer and manufacturer of bioequivalent pharmaceuticals, and as executive vice president and general manager of Perrigo Company Plc, where he was responsible for its $1 billion U.S. pharmaceuticals business, the release said.
“My fellow board members and I are truly excited to welcome Doug to Akorn at this pivotal time for the company,” Board of Directors Chairman Alan Weinstein said. “After a comprehensive search, Doug quickly rose to the top of the list due to his proven track record in helping build businesses, navigate regulatory complexities and guide companies through competitive market environments.”